TEVA's PEG ratio is unavailable because the earnings growth data is negative or zero. Teva- Pharmaceutical Industries last had a PEG ratio of 0.1 in June 2026.
A seven years lookback shows an average PEG ratio of 1.88 for Teva- Pharmaceutical Industries. TEVA reached its maximum PEG ratio of 12.29 during the Jun 2020 quarter over the past seven years. The Mar 2026 quarter had the bottom reading at 0.1, indicating the most optimal growth-adjusted valuation.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.14 | 25.37 | 184.8% |
| 2024 | N/A | N/A | -190% |
| 2023 | N/A | N/A | 77.3% |
| 2022 | N/A | N/A | -678.9% |
| 2021 | 0.19 | 21.08 | 110.4% |
| 2020 | N/A | N/A | -300% |
| 2019 | N/A | N/A | 61.3% |
| 2018 | N/A | N/A | 85.5% |
| 2017 | N/A | N/A | -23,328.6% |
| 2016 | N/A | 517.86 | -96.2% |
| 2015 | N/A | 35.67 | -48.6% |
| 2014 | 0.11 | 16.06 | 140.3% |
| 2013 | N/A | 26.9 | -33.8% |
| 2012 | N/A | 16.6 | -27.4% |
| 2011 | N/A | 13.02 | -16.7% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Sep 2026 | N/A | 88 | -28.6% |
| Jun 2026 | 0.1 | 53.78 | 550% |
| Mar 2026 | 0.1 | 21.99 | 220.2% |
| Dec 2025 | 0.14 | 25.37 | 184.8% |
| Sep 2025 | 0.18 | 32.06 | 174.1% |
| Jun 2025 | N/A | N/A | 65% |
| Mar 2025 | N/A | N/A | -165.1% |
| Dec 2024 | N/A | N/A | -190% |
| Sep 2024 | N/A | N/A | 59.5% |
| Jun 2024 | N/A | N/A | 81% |
| Mar 2024 | N/A | N/A | 72.1% |
| Dec 2023 | N/A | N/A | 77.3% |
| Sep 2023 | N/A | N/A | -81% |
| Jun 2023 | N/A | N/A | -122.1% |
| Mar 2023 | N/A | N/A | -180% |
TEVA's PEG ratio is unavailable because EPS growth data is negative or not present.
Over the last 5 years, TEVA's PEG ratio has settled near 0.14.
TEVA's PEG ratio peaked at 12.29 during the Jun 2020 quarter - the highest in seven years.
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.